×

CD10-activated prodrug compounds

  • US 6,897,034 B2
  • Filed: 06/11/2002
  • Issued: 05/24/2005
  • Est. Priority Date: 06/11/2001
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of designing a prodrug, the method comprising:

  • (1) providing an oligopeptide of the formula (AA)n-AAP2-AAP1-AAP1′

    -(AA)m, wherein;

    n and m are integers, AAP2 represents any amino acid, AAP1 represents any ammo acid, AAP1′

    represents any amino acid, and each AA independently represents an amino acid, (2) linking the oligopeptide at a first attachment site of the oligopeptide to a stabilizing group that hinders cleavage of the oligopeptide by enzymes present in whole blood, and (3) directly or indirectly linking the oligopeptide to a therapeutic agent at a second attachment site of the oligopeptide, wherein steps (2) and (3) may be performed in any order or concurrently and further wherein a conjugate is formed by performance of steps (1) through (3), (4) testing if the conjugate is cleavable by CD10, and (5) selecting the conjugate as a prodrug if the conjugate is cleavable by CD10.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×